These observations support recent investigations of targeting MAPK signaling particularly for treating mCRPC with pathway blockade (75), such as with the MEK1/2 inhibitor trametinib, which has previously been approved for clinical use in melanoma and is currently in a phase 2 clinical trial for patients with CRPC (24). The gene discussed is MAP2K1; the disease is melanoma.